Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings, Inc. (DNA)
:DNA
DNA Analyst Ratings
Moderate Sell
1 Buy
0 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DNA Stock 12 Month Forecast
Average Price Target
$14.00
▲(74.35% Upside)
| Highest Price Target$14.00 | Average Price Target$14.00 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Sell
―
Reiterated
11/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Emergent Biosolutions (NYSE: EBS) and Ginkgo Bioworks Holdings (NYSE: DNA)We are updating our model to incorporate third-quarter results, full-year guidance, and management commentary. For 2025, we now forecast revenue of $173.3 million (from $181.0 million), including Cell Engineering revenue of $133.3 million (from $137.9 million) and $40.0 million in Biosecurity revenue (from $43.0 million). For 2026, we now forecast revenue of $164.8 million (from $194.9 million), including $123.7 million in Cell Engineering revenue (from $150.5 million) and $41.2 million in Biosecurity revenue (from $44.3 million).
TD Cowen
$18→$14
Buy
74.35%
Upside
Reiterated
11/07/25
BTIG
$6→$9
Sell
12.08%
Upside
Reiterated
08/25/25
Morgan Stanley
$10
Hold
24.53%
Upside
Reiterated
05/28/25
Unknown Analyst
Bank of America SecuritiesNot Ranked
Bank of America Securities
$8
Sell
-0.37%
Downside
Reiterated
05/19/25
We tweak our model and reiterate our Underperform rating pending further evidence that DNA can successfully complete its various ongoing operational initiatives. Our DCF-based PO remains at $8...
Unknown Analyst
Bank of America SecuritiesNot Ranked
Bank of America Securities
$8
Sell
-0.37%
Downside
Reiterated
03/03/25
We update our model, and our PO remains $8 based on DCF (14% WACC & 4% terminal growth rate). We reiterate our Underperform rating.
Goldman Sachs
$7
Sell
-12.83%
Downside
Reiterated
02/25/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Sell
―
Reiterated
11/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Emergent Biosolutions (NYSE: EBS) and Ginkgo Bioworks Holdings (NYSE: DNA)We are updating our model to incorporate third-quarter results, full-year guidance, and management commentary. For 2025, we now forecast revenue of $173.3 million (from $181.0 million), including Cell Engineering revenue of $133.3 million (from $137.9 million) and $40.0 million in Biosecurity revenue (from $43.0 million). For 2026, we now forecast revenue of $164.8 million (from $194.9 million), including $123.7 million in Cell Engineering revenue (from $150.5 million) and $41.2 million in Biosecurity revenue (from $44.3 million).
TD Cowen
$18→$14
Buy
74.35%
Upside
Reiterated
11/07/25
BTIG
$6→$9
Sell
12.08%
Upside
Reiterated
08/25/25
Morgan Stanley
$10
Hold
24.53%
Upside
Reiterated
05/28/25
Unknown Analyst
Bank of America SecuritiesNot Ranked
Bank of America Securities
$8
Sell
-0.37%
Downside
Reiterated
05/19/25
We tweak our model and reiterate our Underperform rating pending further evidence that DNA can successfully complete its various ongoing operational initiatives. Our DCF-based PO remains at $8...
Unknown Analyst
Bank of America SecuritiesNot Ranked
Bank of America Securities
$8
Sell
-0.37%
Downside
Reiterated
03/03/25
We update our model, and our PO remains $8 based on DCF (14% WACC & 4% terminal growth rate). We reiterate our Underperform rating.
Goldman Sachs
$7
Sell
-12.83%
Downside
Reiterated
02/25/25
Best Analysts Covering Ginkgo Bioworks Holdings
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+5.27%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.27% per trade.
3 Months
xxx
Success Rate
9/20 ratings generated profit
Average Return
-5.60%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of -5.60% per trade.
1 Year
Success Rate
5/20 ratings generated profit
Average Return
-16.36%
reiterated a sell rating 4 months ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -16.36% per trade.
2 Years
xxx
Success Rate
6/20 ratings generated profit
Average Return
-16.64%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.00% of your transactions generating a profit, with an average return of -16.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DNA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
1
0
0
0
1
Buy
1
2
2
2
1
Hold
15
13
10
7
5
Sell
5
2
2
2
4
Strong Sell
0
0
0
0
0
total
22
17
14
11
11
Each month's total comprises the sum of three months' worth of ratings.
DNA Financial Forecast
DNA Stock Forecast FAQ
What is DNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Ginkgo Bioworks Holdings, Inc.’s 12-month average price target is 14.00.
What is DNA’s upside potential, based on the analysts’ average price target?
Ginkgo Bioworks Holdings, Inc. has 74.35% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DNA a Buy, Sell or Hold?
Ginkgo Bioworks Holdings, Inc. has a consensus rating of Moderate Sell which is based on 1 buy ratings, 0 hold ratings and 2 sell ratings.
What is Ginkgo Bioworks Holdings, Inc.’s price target?
The average price target for Ginkgo Bioworks Holdings, Inc. is 14.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $14.00. The average price target represents 74.35% Increase from the current price of $8.03.
The highest analyst price target is $14.00 ,the lowest forecast is $14.00. The average price target represents 74.35% Increase from the current price of $8.03.
What do analysts say about Ginkgo Bioworks Holdings, Inc.?
Ginkgo Bioworks Holdings, Inc.’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of DNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.